Who are Alphagan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alphagan, Ritalin, Concerta, Trivastal, Iopidine, Cortone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brimonidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Alphagan — Competitive Intelligence Brief

Alphagan (BRIMONIDINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-Adrenergic Agonist. Area: Cardiovascular.

marketed alpha-Adrenergic Agonist Alpha-2C adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Alphagan (BRIMONIDINE) — Senju Pharmaceutical Co., Ltd.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alphagan TARGET	BRIMONIDINE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Alphagan	BRIMONIDINE TARTRATE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Ritalin	methylphenidate	Novartis	marketed		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Concerta	Concerta	Lei Lei, MD	marketed		Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Trivastal	PIRIBEDIL		phase 3	piribedil	Alpha-2C adrenergic receptor
Iopidine	APRACLONIDINE	Harrow Health	marketed	alpha-Adrenergic Agonist	Alpha-2A adrenergic receptor	1987-01-01
Cortone	CORTISONE ACETATE		marketed	alpha-Adrenergic Agonist [EPC]	Corticosteroid-binding globulin	1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-05 — Ritalin · 8840924 · Formulation · US
2032-06-28 — Ritalin · 9072680 · Formulation · US
2032-06-28 — Ritalin · 9089496 · Formulation · US
2038-01-25 — Ritalin · 11166947 · Method of Use · US

Sponsor landscape (alpha-Adrenergic Agonist class)

Senju Pharmaceutical Co., Ltd · 2 drugs in this class
Harrow Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alphagan — Competitive Intelligence Brief. https://druglandscape.com/ci/brimonidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab